Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR39 | O43194 | 5/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
| ▸ | FABP6 | P51161 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700541 | 0.93 | GPR39 (0.54) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL17700175 | 0.91 | GPR39 (0.56) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL17700171 | 0.88 | HIF1A (0.51) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL30794445 | 0.88 | HIF1A (0.51) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL4720018 | 0.88 | HRH4 (0.51) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL13118523 | 0.87 | GRIN2B (0.57) | GPR39GRIN2BCXCR4 | |
| SCHEMBL31610448 | 0.84 | CXCR4 (0.49) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL4522025 | 0.84 | CXCR4 (0.49) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL21641198 | 0.82 | CXCR4 (0.47) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL30585800 | 0.82 | CXCR4 (0.47) | GPR39GRIN2BCXCR4FABP1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-116606292-A | Pyrido [1,2-a ] pyrimidinone derivatives containing sulfonamide unit, preparation method and application thereof | 贵州大学 | 2023-08-18 | — | — | CN | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20100022559-A1 | BISOXIMES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | GPR39 263/4885GRIN2B 350/4885CXCR4 2856/4885 |
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | GPR39 359/4885GRIN2B 265/4885CXCR4 220/4885 |
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | GPR39 3/4885GRIN2B 3956/4885CXCR4 1021/4885 |
| US-20240368137-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | GPR39 263/4885GRIN2B 350/4885CXCR4 2856/4885 |
| US-12012398-B2 | Bicyclic compounds as androgen receptor modulators | AR, FSHR, NCOA3 | GPR39 207/4885GRIN2B 316/4885CXCR4 2949/4885 |
| US-20100022559-A1 | BISOXIMES AS FUNGICIDES | DDT, FHIT, CYP4X1 | GPR39 3498/4885GRIN2B 1952/4885CXCR4 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.